Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > March 30, 2020
Daily News
March 30, 2020
- Daiichi Sankyo Files Yescarta, Second CAR-T Therapy in Japan
March 30, 2020
- Japan Hammers Out New 5-Year Health, Medical Strategy
March 30, 2020
- New Stable Supply Panel Wants to Define “Key Drugs” by This Summer
March 30, 2020
- PMDA Asking Companies to Seek Advice for Trial Rescheduling
March 30, 2020
- Daiichi Sankyo Shares Anti-Coronavirus Measures, Development Plan
March 30, 2020
- Daiichi Sankyo, Kitasato Pharma End Flu Vaccine Collaboration
March 30, 2020
- India Lockdown Derails Japan-Bound APIs, Intermediate Exports
March 30, 2020
- PM Abe Says Japan to Start Registration Trial for Avigan for COVID-19, Plans Production Boost
March 30, 2020
- Researchers Unlock SAL Inhibitory Mechanism of Obesity Med Orlistat; Potential Treatment for MRSA/Atopic Dermatitis
March 30, 2020
- US FDA Accepts Xofluza’s Granule Version, Pediatric Use for Review: Shionogi
March 30, 2020
- Kissei Licenses CG Oncology's Oncolytic Viral Therapy in Asia Excluding China
March 30, 2020
- Ex-Tokyo Tech President Yoshinao Mishima Named AMED Chief from April
March 30, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…